MML Investors Services LLC decreased its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 5.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 41,312 shares of the medical research company’s stock after selling 2,428 shares during the period. MML Investors Services LLC’s holdings in Exact Sciences were worth $1,342,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Canada Pension Plan Investment Board increased its holdings in Exact Sciences by 137.6% in the third quarter. Canada Pension Plan Investment Board now owns 187,150 shares of the medical research company’s stock valued at $6,081,000 after purchasing an additional 108,393 shares during the last quarter. Integral Health Asset Management LLC bought a new position in Exact Sciences during the 3rd quarter worth approximately $4,874,000. Exos TFP Holdings LLC acquired a new position in Exact Sciences during the third quarter valued at approximately $158,000. FORA Capital LLC bought a new stake in Exact Sciences in the third quarter valued at approximately $275,000. Finally, Eisler Capital UK Ltd. acquired a new stake in Exact Sciences in the third quarter worth $98,000. Institutional investors own 90.30% of the company’s stock.
Insider Activity
In other Exact Sciences news, EVP Sarah Condella sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the executive vice president now owns 85,090 shares of the company’s stock, valued at $5,105,400. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Kevin T. Conroy sold 4,527 shares of the firm’s stock in a transaction dated Monday, February 13th. The shares were sold at an average price of $64.55, for a total transaction of $292,217.85. Following the completion of the sale, the chief executive officer now owns 1,173,105 shares in the company, valued at approximately $75,723,927.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sarah Condella sold 1,000 shares of the company’s stock in a transaction dated Monday, January 9th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the executive vice president now owns 85,090 shares in the company, valued at approximately $5,105,400. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 57,126 shares of company stock valued at $3,590,586. 1.30% of the stock is owned by company insiders.
Analysts Set New Price Targets
Exact Sciences Stock Up 0.2 %
EXAS stock opened at $62.45 on Thursday. The company has a market cap of $11.13 billion, a price-to-earnings ratio of -17.64 and a beta of 1.42. Exact Sciences Co. has a twelve month low of $29.27 and a twelve month high of $76.94. The business has a 50 day moving average price of $61.63 and a two-hundred day moving average price of $46.84. The company has a quick ratio of 2.09, a current ratio of 2.38 and a debt-to-equity ratio of 0.73.
Exact Sciences (NASDAQ:EXAS – Get Rating) last released its earnings results on Tuesday, February 21st. The medical research company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.18. Exact Sciences had a negative net margin of 29.92% and a negative return on equity of 19.76%. The business had revenue of $553.00 million during the quarter, compared to analysts’ expectations of $525.61 million. During the same period last year, the business earned ($1.28) earnings per share. The firm’s revenue was up 16.7% on a year-over-year basis. Analysts anticipate that Exact Sciences Co. will post -2.85 EPS for the current fiscal year.
About Exact Sciences
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
Featured Stories
- Get a free copy of the StockNews.com research report on Exact Sciences (EXAS)
- Jack in the Box Pops On Tasty Results, Robust Outlook
- How Low Can Lowe’s Companies Go?
- Ambarella: An AI Play In The Making
- Terran Orbital’s New $2.4 Billion Contract is a Game Changer
- Wendy’s Price Firms After Sizzling Quarter And Juicy Outlook
Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXAS – Get Rating).
Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
